Cardiovascular implantable electronic devices have revolutionized the management of heart
failure with reduced ejection fraction. New device generations tend to be launched every few …

Implantable cardioverter defibrillator (ICD) trials were initially limited to survivors of sudden
death. The focus of defibrillator trials in the last decade has been in prophylactic …

Supported by extensive clinical evidence, electrical device therapy for heart failure has had
impressive development during the last 15 years. Patients with chronic heart failure (CHF) …

Device therapy for heart failure has a spectacular development during the last 10 years.
Patients with chronic heart failure might benefit from electrical therapy with a view to:(i) …

Despite advances in heart failure treatment, this condition remains a relevant medical issue
and is associated with a high morbidity and mortality. The cause of death in patients …

Background Cardiac resynchronization therapy (CRT) is one of the most successful heart
failure therapies to emerge in the last 25 years and is applicable to≏ 25–30% of patients …

Introduction/background Implantable cardiac devices are widely used in chronic heart failure
(CHF) therapy. This review covers current CHF treatment with electronic cardiac devices …

Cardiac resynchronisation therapydefibrillators (CRT-D) would seem the obvious choice for
patients with heart failure with reduced ejection fraction, given implantable cardioverter …

Pacemakers and implantable cardioverter defibrillators (ICDs) have revolutionized
cardiology by providing life-saving interventions for patients with cardiac rhythm …

Aims Cardiac resynchronization therapy (CRT) is an effective treatment for a subset of
patients with chronic heart failure. Data on the benefit of CRT in heart failure patients with …